Gilternib 40 mg (Gilteritinib) Tablets

Introduction:

Gilternib 40 mg, manufactured by Everest Pharmaceuticals Ltd and supplied by Orio Pharma, is a targeted therapy specifically designed for the treatment of acute myeloid leukemia (AML) in patients with FLT3 mutations. Containing Gilteritinib, Gilternib 40 mg works by inhibiting the FLT3 receptor tyrosine kinase, a protein that plays a crucial role in the proliferation and survival of leukemia cells. This targeted approach makes Gilternib particularly effective in managing AML, offering improved survival rates and quality of life for patients with FLT3 mutation-positive tumors.

Manufacturing Excellence of Everest Pharmaceuticals Ltd.:

Everest Pharmaceuticals Ltd. is committed to producing high-quality pharmaceutical products that adhere to stringent international standards. The development of Gilternib 40 mg reflects Everest’s dedication to advancing cancer treatments through innovative research, rigorous quality control, and adherence to best manufacturing practices. Their focus on safety and efficacy ensures that Gilternib 40 mg is a reliable and effective therapy for patients battling acute myeloid leukemia.

Mechanism of Action:

Gilternib 40 mg contains Gilteritinib, a selective inhibitor of the FLT3 receptor tyrosine kinase. FLT3 mutations are commonly associated with poor prognosis in AML, leading to increased proliferation of leukemia cells and resistance to conventional chemotherapy. By inhibiting the FLT3 receptor, Gilteritinib interferes with the leukemia cell’s ability to grow and survive, inducing apoptosis (programmed cell death) and reducing tumor burden. This targeted action is particularly effective in treating FLT3 mutation-positive AML, providing a new option for patients with relapsed or refractory disease.

Clinical Applications:

Gilternib 40 mg is indicated for the treatment of:

• Acute Myeloid Leukemia (AML): Gilternib is used as a targeted therapy for adult patients with relapsed or refractory AML who have a FLT3 mutation. It is especially beneficial for patients who have not responded to prior treatments or who have relapsed after initial therapy.

Clinical studies have demonstrated that Gilternib 40 mg significantly improves survival and remission rates in patients with FLT3 mutation-positive AML, providing a more effective and targeted alternative to traditional chemotherapy.

Dosage and Administration:

The recommended dosage of Gilternib 40 mg is one or more tablets taken once daily, depending on the prescribed dose. The tablet should be swallowed whole with water, and it can be taken with or without food. It is crucial for patients to follow their healthcare provider’s instructions closely and adhere to the prescribed dosing schedule to achieve the best possible treatment outcomes. Regular monitoring of blood counts, liver function, and other clinical parameters is essential to assess the response to therapy and manage any potential side effects.

Benefits of Gilternib 40 mg:

• Targeted AML Therapy: Gilternib 40 mg provides a precision approach to treating FLT3 mutation-positive AML by specifically inhibiting the FLT3 receptor tyrosine kinase, which is crucial for leukemia cell survival.
• Improved Survival Rates: Clinical trials have demonstrated that Gilternib 40 mg improves overall survival and remission rates in patients with relapsed or refractory AML.
• Oral Administration: Gilternib is administered orally, offering a convenient treatment option that can be easily integrated into daily routines, enhancing patient adherence to therapy.
• Effective in FLT3 Mutations: Gilternib 40 mg is particularly effective in patients with FLT3 mutations, offering a precision medicine approach that improves outcomes compared to standard chemotherapy.

Supplier: Orio Pharma

Orio Pharma ensures that Gilternib 40 mg is readily available to healthcare providers and patients, offering reliable access to this essential cancer therapy. Their commitment to efficient supply and distribution supports effective treatment and improved patient outcomes in managing acute myeloid leukemia.

Conclusion:

Gilternib 40 mg (Gilteritinib) by Everest Pharmaceuticals Ltd, supplied by Orio Pharma, represents a significant advancement in the treatment of acute myeloid leukemia. This targeted therapy not only provides a precise approach to managing FLT3 mutation-positive AML but also offers the potential for improved survival and quality of life for patients. By incorporating Gilternib into their treatment plans, healthcare providers can offer patients a comprehensive and effective strategy for managing AML, leading to better health outcomes.